DiaMedica Therapeutics Inc. Common Stock
$6.85
$0.22 (+3.32%)
$6.67Day Range$7.00
Key Statistics
Market Cap
$357.53M
Shares Outstanding
53.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 29, 2007
Round Lot
100
Locale
US
Trading Data
Day Open
$6.75
Day High
$7.00
Day Low
$6.67
Volume
257.8K
VWAP
$6.88
Prev Close
$6.63
Transactions
--
Acc. Volume
--
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
PHARMACEUTICAL PREPARATIONSSIC 283435 employees301 CARLSON PARKWAY, MINNEAPOLIS, MN, 55305(763) 496-5454IPO Nov 29, 2007US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001401040
- Composite FIGI
- BBG000LP4YD7
- Share Class FIGI
- BBG001SQ3K65
- Ticker Root
- DMAC
- SIC Code
- 2834
About DiaMedica Therapeutics Inc. Common Stock (DMAC) Stock
DiaMedica Therapeutics Inc. Common Stock (DMAC) closed the 2026-09-17 session at $6.85, up 3.32% versus the previous close (+0.22). The stock opened at $6.75 and traded between $6.67 and $7.00 during that session. Session trading volume was 258K shares. The volume-weighted average price (VWAP) is $6.88.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
DiaMedica Therapeutics Inc. Common Stock has a market capitalization of $357.5 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. DMAC is listed on the XNAS exchange. The company employs approximately 35 people. DiaMedica Therapeutics Inc. Common Stock is headquartered in MINNEAPOLIS, MN. The recorded listing date is 2007-11-29.
On this page you can find market DMAC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.